In conclusion, our results support the view that activation of the JAK2-STAT2 pathway drives the development of obesity, insulin resistance, associated end-organ injury and, most notably, highlights the potential repurposing of JAK inhibitors already approved for rheumatoid arthritis as promising treatment options in the clinical context of metabolic diseases. The gene discussed is JAK2; the disease is obesity disorder.